Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 10/20 | 0.45 |
| ▸ | CTSL | P07711 | 7/20 | 0.45 |
| ▸ | CTSK | P43235 | 6/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6403319 | 0.92 | USP30 (0.45) | CTSSCTSLCTSKUSP30RAB9A | |
| SCHEMBL6402653 | 0.91 | CTSS (0.47) | CTSSCTSLCTSKLPAR1LIMK2 | |
| SCHEMBL6403176 | 0.88 | LPAR1 (0.45) | CTSSCTSLCTSKLPAR1LIMK2 | |
| SCHEMBL6405206 | 0.87 | CTSS (0.44) | CTSSCTSLCTSKLPAR1LIMK2 | |
| SCHEMBL6401544 | 0.83 | MEN1 (0.48) | NPC1RAB9A | |
| SCHEMBL6401355 | 0.80 | CTSS (0.41) | CTSSCTSLCTSKUSP30MMP13 | |
| SCHEMBL6401362 | 0.80 | RAB9A (0.45) | NPC1RAB9A | |
| SCHEMBL6401366 | 0.76 | KEAP1 (0.41) | LPAR1LIMK2 | |
| SCHEMBL6407189 | 0.74 | MMP3 (0.41) | LPAR1LIMK2 | |
| SCHEMBL6403273 | 0.73 | LMNA (0.49) | CTSSCTSLCTSKUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900237-B2 | Sulfonamide compounds as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | claimed |
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | Celera Corporation | 2003-08-21 | — | — | US | claimed |
| US-6900237-B2 | Sulfonamide compounds as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | Celera Corporation | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | PRSS1, PRSS3, SPINT2 | CTSS 13/4885CTSL 22/4885CTSK 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.